GI & Colorectal Cancer Surgery — Stomach, Colon, Rectum, Pancreas, Liver | Dr. Vinod T. Gore

Overview

GI & HPB Oncology Surgery

Gastrointestinal cancers — of the stomach, colon, rectum, pancreas, liver, gallbladder, and bile ducts — collectively represent the largest group of solid organ malignancies treated by surgical oncology. Each cancer has its own surgical strategy, neoadjuvant approach, and reconstruction technique, requiring broad expertise and experience.

Dr. Gore's comprehensive GI oncology training at Tata Memorial Hospital, Mumbai — covering gastric, colorectal, pancreatic, hepatobiliary, and peritoneal surface malignancies — together with FARIS robotic surgery credentials and extensive experience at Sahyadri Manipal Hospitals, enables him to offer the complete spectrum of GI cancer surgery including complex HPB procedures, robotic colorectal surgery, and HIPEC for peritoneal disease.

A key innovation in his colorectal surgery practice is the routine use of ICG fluorescence for anastomotic perfusion assessment — real-time confirmation that the bowel anastomosis is adequately perfused before closing, significantly reducing anastomotic leak rates after rectal surgery.

🩺

A Note from Dr. Gore GI Surgical Oncologist · Tata Memorial Trained

GI oncology surgery demands not just technical skill but careful judgement — knowing when to operate, when to give chemotherapy first, how to select the right reconstruction, and how to manage complications. At Tata Memorial I operated under some of India's best GI surgical oncologists — that training shapes every complex case I take on.

For rectal cancer specifically, achieving a complete Total Mesorectal Excision (TME) — undistorted, with intact mesorectal fascia — is the single most important determinant of local recurrence. Robotic TME gives me the best pelvic visualisation I have ever had for this operation. ICG perfusion confirmation before I close the anastomosis is now routine — it has made a real difference.

— Dr. Vinod T. Gore, MBBS MS FAIS FIAGES FARIS (Edin)

Stomach Oncology

Gastric Cancer Surgery — Gastrectomy & D2 Dissection

Gastric cancer (stomach cancer) requires surgical resection with systematic D2 lymph node dissection — the global standard for curative gastric cancer surgery. The extent of stomach removal depends on tumour location.

Robotic Gastrectomy — Full Information

Complete details of robotic total and subtotal gastrectomy for gastric cancer — D2 dissection, reconstruction, recovery, and outcomes by Dr. Vinod T. Gore.

bestroboticsurgeonpune.in/Robotic Gastrectomy

Know More →

Gastric adenocarcinoma accounts for the majority of stomach cancers and presents most commonly in the antrum or corpus. For locally advanced resectable gastric cancer (Stage II–III), the current standard is perioperative FLOT chemotherapy — 4 cycles before and 4 cycles after surgery (Docetaxel, Oxaliplatin, Leucovorin, 5-FU) — which significantly improves resection rates and survival compared to surgery alone.

The surgical procedure is determined by tumour location. For antral tumours — subtotal gastrectomy (removing 75–80% of the stomach) with Roux-en-Y or Billroth II reconstruction provides equivalent cure with better functional outcomes. For body or fundal tumours or diffuse-type gastric cancer — total gastrectomy with Roux-en-Y oesophagojejunostomy is required.

The most important component of any curative gastric cancer operation is a systematic D2 lymphadenectomy — removing all N1 (perigastric) and N2 (coeliac axis, hepatic artery, left gastric, splenic) nodal stations, with a minimum of 15 lymph nodes examined for accurate staging.

D2 Lymphadenectomy — The Gold Standard

D2 dissection removes all N1 perigastric nodes AND N2 nodes along the coeliac axis, left gastric artery, common hepatic artery, and splenic artery — requiring dissection of nodal stations 1–12. International guidelines (NCCN, ESMO, JGCA) recommend D2 as the minimum standard for any curative-intent gastric cancer surgery. Robotic D2 dissection is technically superior to open — providing magnified vision of the coeliac axis anatomy and reducing intraoperative blood loss.

Subtotal Gastrectomy

Removal of 75–80% of the stomach — preserving the fundus. For antral tumours with ≥5cm clearance from the tumour. Better long-term nutrition and quality of life than total gastrectomy.

Antral Tumours

Total Gastrectomy

Complete stomach removal — for proximal, body, or diffuse-type gastric cancer. Roux-en-Y oesophagojejunostomy reconstruction. Jejunal pouch may be fashioned to improve reservoir capacity.

Body / Fundal / Diffuse

Proximal Gastrectomy

For selected early proximal gastric cancers — removing the upper stomach while preserving the antrum and pylorus. Prevents bile reflux while maintaining gastric reservoir. Double-tract or oesophagogastrostomy reconstruction.

Proximal EGC

Robotic Gastrectomy with D2 LND

da Vinci robotic approach — superior magnified visualisation of coeliac axis, hepatic artery, and left gastric nodes. Precise lymph node dissection with reduced blood loss. Equivalent oncological outcomes with faster recovery.

Robotic — Preferred

Neoadjuvant Strategy

FLOT

Perioperative (preferred): Docetaxel + Oxaliplatin + Leucovorin + 5-FU. 4 pre-op + surgery + 4 post-op cycles. FLOT4 trial — superior to ECF/ECX

HER2+

Add Trastuzumab: For HER2-positive gastric cancer (15–20%) — Trastuzumab added to perioperative chemotherapy

Early (T1)

Surgery alone: For Stage IA — surgery without neoadjuvant. Consider endoscopic submucosal dissection for T1a low-grade lesions

Most Common GI Cancer in India

Colorectal Cancer Surgery — Colon & Rectum

Colorectal cancer is the third most common cancer worldwide. Surgery — guided by anatomical principles of embryological planes, adequate margins, and systematic lymphadenectomy — is the cornerstone of curative treatment.

Colon Cancer Surgery

The operation for colon cancer is determined by the tumour location — each segment of the colon has specific vascular anatomy that defines the resection boundaries. All colon cancer surgery includes systematic mesocolic lymph node dissection along the supplying vessel (Complete Mesocolic Excision — CME).

Right Hemicolectomy

For caecal, ascending colon, and hepatic flexure tumours — removes right colon with ileocolic, right colic, and right branch of middle colic vessels. Ileotransverse anastomosis. Extended right hemicolectomy for transverse colon tumours.

Left Hemicolectomy

For descending colon tumours — removes left colon based on left colic artery. High ligation of inferior mesenteric artery (IMA) with para-aortic node clearance when indicated for staging.

Sigmoid Colectomy / High Anterior Resection

For sigmoid colon and upper rectal tumours above the peritoneal reflection. Sigmoid removal with IMA high ligation. Primary colorectal anastomosis without stoma in most patients.

The Most Technically Demanding GI Cancer Operation

Rectal Cancer Surgery — TME, LAR & APR

Rectal cancer surgery requires the most precise anatomical dissection in all of colorectal surgery. The quality of the Total Mesorectal Excision (TME) — not just the fact of operating — determines local recurrence rates and patient survival.

Total Mesorectal Excision (TME) — The Guiding Principle

The most important technical standard in rectal cancer surgery

TME means sharp dissection along embryological fascial planes — removing the rectum enclosed within an intact mesorectal fascia envelope, without breach or perforation of the mesorectal package. All mesorectal lymph nodes, lymphatics, and fatty tissue are included. A complete, intact TME specimen (Grade 3) reduces local recurrence from 25–30% (blunt dissection) to <5%. This is the single most important technical standard in rectal cancer surgery — and the area where robotic surgery provides the most compelling advantage, through superior 3D pelvic vision and articulated instrument access deep in the pelvis.

Neoadjuvant Treatment Before Rectal Cancer Surgery

LCRT

Long-course Chemoradiation (LCRT): 45–50.4 Gy + concurrent Capecitabine or 5-FU over 5 weeks → surgery after 8–12 weeks. For T3–T4 or N+ rectal cancer. Achieves tumour downstaging. pCR in 15–20% enables "watch and wait" strategy.

SCRT

Short-course Radiotherapy (SCRT): 25 Gy in 5 fractions → immediate or delayed surgery. For resectable T3 rectal cancer. RAPIDO trial — SCRT + consolidation FOLFOX + surgery = superior systemic disease control.

Watch & Wait

Non-operative management after clinical complete response: For patients with cCR after LCRT — intensive surveillance (MRI, endoscopy) with deferred surgery. Avoids colostomy or anterior resection in highly selected patients.

Robotic Low Anterior Resection (LAR) — Full Information

Robotic TME, sphincter-preserving rectal resection, ICG anastomotic perfusion — complete details at Dr. Gore's robotic surgery website.

bestroboticsurgeonpune.in/Robotic Low Anterior Resection

Know More →

Robotic Abdominoperineal Resection (APR) — Full Information

Robotic APR for low rectal cancer — cylindrical APR, perineal dissection, end colostomy — complete details at Dr. Gore's robotic surgery website.

bestroboticsurgeonpune.in/Robotic APR Surgery

Know More →

Low Anterior Resection (LAR)

Sphincter-Preserving Rectal Resection — for Mid and Upper Rectal Tumours

LAR removes the rectum and sigmoid colon with a full TME, preserving the anal sphincter complex and restoring bowel continuity with a colorectal or coloanal anastomosis. A defunctioning loop ileostomy is fashioned to protect the low anastomosis — closed 8–12 weeks later once anastomotic healing is confirmed by CT enema or flexible sigmoidoscopy.

✓Tumours of the upper and mid rectum (≥3–4cm from anal verge with adequate distal margin)
✓Complete TME with intact mesorectal fascia — the technical goal
✓Robotic approach — superior 3D pelvic visualisation, precise autonomic nerve preservation
✓ICG fluorescence confirms anastomotic perfusion before stapling
✓Temporary loop ileostomy — reversed at 8–12 weeks post-operatively

Outcome: Bowel continuity preserved — patient avoids permanent colostomy. Local recurrence <5% with complete TME + neoadjuvant chemoradiation.

Abdominoperineal Resection (APR)

For Low Rectal Tumours — When Sphincter Cannot Be Preserved

APR removes the rectum, sigmoid colon, and the entire anal canal and sphincter complex — performed through combined abdominal and perineal approaches. The sigmoid colon is brought out as a permanent end colostomy. Indicated when the tumour is too close to or involves the sphincter — inadequate distal margin would compromise oncological clearance if LAR were attempted.

✓Low rectal tumours <3cm from anal verge with sphincter involvement or inadequate distal margin
✓Cylindrical APR (extra-levator APR) — wider perineal resection for better CRM clearance
✓Robotic abdominal phase — superior TME, precise autonomic nerve preservation in pelvis
✓Perineal reconstruction with biological mesh or VRAM flap for large perineal defects
✓Permanent end sigmoid colostomy — well-managed with modern stoma care

Outcome: Complete oncological resection of low rectal cancer with sphincter involvement. Quality APR with cylindrical technique achieves CRM negative in >85% of cases.

💡

ICG Fluorescence — Anastomotic Perfusion Assessment: Dr. Gore routinely performs intraoperative ICG fluorescence imaging (Firefly) before completing the colorectal or coloanal anastomosis — confirming adequate blood supply to the bowel ends in real time. Ischaemic bowel (dark on NIR) is identified and the anastomotic level adjusted before the stapler is fired — significantly reducing anastomotic leak rates. Learn more about ICG fluorescence →

Most Complex GI Cancer Operation

Pancreatic Cancer — Whipple's Procedure & Beyond

Pancreatic ductal adenocarcinoma (PDAC) is one of the most challenging cancers to treat. Only 15–20% of patients are resectable at presentation. Surgery — when feasible — offers the only chance of cure.

Robotic Whipple's Surgery — Full Information

Complete details of robotic pancreaticoduodenectomy — patient selection, procedure steps, reconstruction, recovery, and outcomes by Dr. Vinod T. Gore, FARIS Edinburgh.

bestroboticsurgeonpune.in/Robotic Whipple's surgery

Know More →

Pancreatic cancer is staged by resectability — resectable, borderline resectable, locally advanced, or metastatic — based on the relationship of the tumour to the superior mesenteric artery (SMA), superior mesenteric vein (SMV), portal vein, and coeliac axis. For borderline resectable disease, neoadjuvant FOLFIRINOX (Oxaliplatin + Irinotecan + Leucovorin + 5-FU) is the current standard — attempting to convert to resectable status.

Whipple's procedure (pancreaticoduodenectomy) is one of the most technically demanding operations in surgery — removing the head of pancreas, duodenum, bile duct, and gallbladder, with reconstruction requiring three separate anastomoses (pancreaticojejunostomy, hepaticojejunostomy, and gastrojejunostomy or duodenojejunostomy). Operative mortality at high-volume centres is <3%; the major morbidity is post-operative pancreatic fistula (POPF), which occurs in 15–25% of cases.

For tumours of the body or tail — distal pancreatectomy with splenectomy is performed. For multifocal disease or main duct IPMN — total pancreatectomy may be required, rendering the patient permanently insulin-dependent.

Whipple's Operation — The Resection & Reconstruction

Staging Laparotomy / Laparoscopy

Assess resectability — SMA, SMV, portal vein relationship. Rule out peritoneal or liver metastases not seen on CT. Intraoperative ultrasound for liver deposits.

Pancreaticoduodenectomy — Resection

En-bloc removal of pancreatic head, duodenum (1st–3rd parts), distal bile duct, gallbladder, distal stomach (classical Whipple's) or pylorus-preserving (PPPD). Lymphadenectomy of hepatoduodenal ligament, superior mesenteric nodes.

Pancreaticojejunostomy — Critical Anastomosis

Remnant pancreas anastomosed to jejunum (duct-to-mucosa or invagination technique). The most technically demanding step — the quality of this anastomosis determines the risk of pancreatic fistula.

Hepaticojejunostomy

Bile duct anastomosed to jejunum — restores biliary drainage. Single-layer absorbable suture technique. Bile leak rate 3–5% at expert centres.

🍽️

Gastrojejunostomy / Duodenojejunostomy

GI continuity restored — stomach or duodenum (PPPD) anastomosed to jejunum on the same Roux limb. Delayed gastric emptying (DGE) is the most common functional complication (15–20%).

Recovery & Adjuvant Treatment

7–10 days hospital. Adjuvant mFOLFIRINOX (6 months) or Gemcitabine + Capecitabine started 6–12 weeks post-operatively. Robotic approach — 5–7 day stay, less blood loss.

Hepatobiliary Oncology

Liver, Gallbladder & Bile Duct Cancer Surgery

Hepatopancreatobiliary (HPB) cancers — of the liver, gallbladder, and bile ducts — require specialised surgical expertise in hepatic resection, biliary reconstruction, and vascular control.

Hepatocellular Carcinoma (HCC)

Primary liver cancer — arising on a background of cirrhosis (HBV, HCV, NASH) in most cases. Surgical resection is the curative option for non-cirrhotic patients or those with well-compensated Child-Pugh A cirrhosis and adequate future liver remnant. ICG retention by HCC under NIR fluorescence allows precise tumour margin delineation during resection.

Segmentectomy / Sectionectomy — anatomical hepatectomy preserving functional parenchyma

Formal right / left hepatectomy — for large or multi-segment tumours

ICG fluorescence margin assessment — tumour delineation under NIR

Portal vein embolisation (PVE) — for inadequate future liver remnant (<30%)

Colorectal Liver Metastases

The liver is the most common site of colorectal cancer metastasis — and liver resection for colorectal liver metastases is potentially curative in selected patients. 5-year survival after resection is 35–50%. Modern oncosurgical strategy allows staged or simultaneous resection of the primary colonic tumour and liver metastases.

Wedge resection / segmentectomy — for peripheral metastases with adequate margin

Major hepatectomy — for centrally located or multiple metastases

Two-stage hepatectomy — for bilobar metastases requiring sequential resection

Simultaneous colorectal + liver resection — selected patients, combined team approach

Gallbladder Cancer

Gallbladder cancer is often diagnosed incidentally after laparoscopic cholecystectomy (T1b or higher) — requiring re-operation with radical cholecystectomy. Port site excision is mandatory when cholecystectomy was performed laparoscopically for an unsuspected gallbladder cancer, to remove potentially seeded port sites.

Simple cholecystectomy — for T1a (mucosa only), no further surgery needed

Radical cholecystectomy — T1b+: liver bed resection (segment IVb + V) + lymphadenectomy of hepatoduodenal ligament

Port site excision — mandatory for laparoscopically resected incidental GBC T1b+

Bile duct resection — for tumours involving the cystic duct or CBD junction

Cholangiocarcinoma

Bile duct cancer — classified as perihilar (Klatskin tumour, most common), intrahepatic, or distal. Perihilar cholangiocarcinoma (involving the hilum) is among the most technically demanding hepatobiliary operations — requiring en-bloc hepatectomy with bile duct resection and biliary reconstruction with a Roux-en-Y hepaticojejunostomy.

Intrahepatic CCA — major hepatectomy with clear margins

Perihilar CCA — right or left hepatectomy + caudate lobe + bile duct excision + Roux-en-Y

Distal CCA — Whipple's pancreaticoduodenectomy

Biliary stenting — pre-operative for obstructive jaundice if >200 µmol/L

Peritoneal Metastases — HIPEC

For colorectal cancer with peritoneal spread, appendiceal mucinous tumours, and selected gastric cancer peritoneal metastases — Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) offers the best chance of long-term survival in appropriately selected patients.

Colorectal peritoneal metastases — CRS + HIPEC (Oxaliplatin or Mitomycin C)

Pseudomyxoma peritonei — CRS + HIPEC, excellent long-term outcomes

Gastric peritoneal metastases — selected cases with low PCI

Electrochemotherapy (ECT)

For unresectable liver tumours or cutaneous / subcutaneous GI cancer deposits — Electrochemotherapy using Bleomycin with targeted electroporation delivers dramatically enhanced local drug concentrations, achieving tumour control without systemic toxicity. Dr. Gore pioneered ECT in Asia (2013) and uses it for selected GI cancer deposits.

Hepatic deposits not suitable for surgery or ablation

Cutaneous / subcutaneous GI cancer recurrence

Chest wall deposits from GI primaries

Patient Questions

Frequently Asked Questions

I have been diagnosed with rectal cancer. Will I need a permanent colostomy?▼

Not necessarily — this depends entirely on the location of the tumour in the rectum. For mid and upper rectal tumours (≥3–4cm from the anal verge with adequate distal margin), sphincter-preserving LAR (Low Anterior Resection) is performed — the rectum is removed but bowel continuity is restored and you wake up without a permanent colostomy. You will have a temporary ileostomy (loop) for 8–12 weeks to protect the anastomosis, which is then reversed. For low rectal tumours involving or too close to the sphincter, APR with a permanent colostomy is required. Dr. Gore will review your MRI and determine the correct operation for your specific tumour level and characteristics.

What is a Whipple's operation and how long does recovery take?▼

Whipple's procedure (pancreaticoduodenectomy) removes the head of the pancreas, the duodenum, the bile duct, and the gallbladder, then reconstructs the GI tract with three new connections. It is one of the most complex operations in surgery — taking 4–7 hours. Hospital stay is 7–10 days after open surgery, or 5–7 days after robotic Whipple's. Full recovery takes 6–8 weeks. Adjuvant chemotherapy (mFOLFIRINOX for 6 months) starts 6–12 weeks after surgery. Major complications include pancreatic fistula (15–25%), delayed gastric emptying (15–20%), and bile leak (3–5%) — all managed without re-operation in most cases.

My pancreatic cancer is "borderline resectable." Does this mean I can't be operated?▼

Borderline resectable means the tumour is touching but not encasing the superior mesenteric artery or portal vein — surgery is technically feasible but risky for positive margins. The current approach is to give neoadjuvant chemotherapy (FOLFIRINOX — 4–6 cycles) first, aiming to downstage the tumour away from these vessels, then reassess with repeat CT/MRI. If the tumour responds and pulls away from the vessels, surgery becomes much safer with a higher likelihood of achieving clear margins (R0 resection). This strategy has converted many borderline tumours into resectable ones. Dr. Gore will review your cross-sectional imaging to assess your specific resectability status.

My colonoscopy found cancer. Do I need chemotherapy before surgery?▼

For colon cancer — generally no. Most resectable colon cancers go directly to surgery, with adjuvant chemotherapy (CAPOX or FOLFOX) given after surgery if the pathology shows Stage III (lymph node positive) or high-risk Stage II disease. For rectal cancer — neoadjuvant chemoradiation (LCRT) or short-course radiotherapy (SCRT) is recommended for Stage II–III rectal tumours before surgery. This shrinks the tumour, reduces local recurrence risk, and may even achieve a complete pathological response (pCR), allowing some patients to avoid surgery entirely under close surveillance.

What is the advantage of robotic surgery for rectal cancer compared to open or laparoscopic?▼

Rectal cancer surgery requires the most precise anatomical dissection deep in the narrow pelvis — which is exactly where robotic surgery excels most. The da Vinci system provides 10–15× magnified 3D vision of the pelvic planes, wristed instruments with full rotational range in the confined pelvic space, and the ability to identify and preserve the pelvic autonomic nerves (hypogastric plexus) that control bladder and sexual function. Robotic TME consistently achieves superior mesorectal plane dissection quality compared to laparoscopic TME — with lower positive circumferential resection margin (CRM) rates, less blood loss, and equivalent or better functional outcomes for bladder and sexual function preservation.

My gallbladder cancer was found after cholecystectomy. Do I need another operation?▼

It depends on the pathological T stage. For T1a (mucosa only) — simple cholecystectomy is curative, no further surgery needed. For T1b (muscle invasion) and above — re-operation is required: radical cholecystectomy with resection of the gallbladder bed (liver segments IVb and V) and hepatoduodenal lymphadenectomy. If the original cholecystectomy was performed laparoscopically, port site excision is also mandatory — all three laparoscopic port sites must be excised en bloc, as bile spillage during cholecystectomy seeds the port sites with cancer cells in a significant proportion of cases. This should be done within 6–8 weeks of the original operation.

#BestCancerSurgeonInPune #BestSurgicalOncologistInPune #BestCancerSpecialistInPune #BestCancerDoctorInPune #BestOncologistInPune #BestOncosurgeonInPune #BestOncoSurgeonInPune #TopCancerSurgeonInPune #TopSurgicalOncologistInPune #TopOncologistInPune #TopCancerSpecialistInPune #TopCancerDoctorInPune #TopOncosurgeonInPune #SeniorCancerSurgeonPune #SeniorOncologistPune #SeniorSurgicalOncologistPune #SeniorCancerSpecialistPune #LeadingCancerSurgeonPune #LeadingOncologistPune #LeadingCancerSpecialistPune #ExpertCancerSurgeonPune #ExpertOncologistPune #ExperiencedCancerSurgeonPune #ExperiencedOncologistPune #RenownedCancerSurgeonPune #RenownedOncologistPune #FamousCancerSurgeonPune #TrustedCancerDoctorPune #MostExperiencedCancerSurgeonPune #MostTrustedOncologistPune #CancerSurgeonInPune #OncologistInPune #SurgicalOncologistInPune #CancerSpecialistInPune #CancerDoctorInPune #OncoSurgeonPune #OncosurgeonPune #CancerSurgeonNearMe #OncologistNearMe #BestOncologistNearMe #CancerDoctorNearMe #SurgicalOncologistNearMe #CancerSpecialistNearMe #PuneBestCancerSurgeon #PuneTopOncologist #PuneCancerSurgeryExpert #PuneSurgicalOncology #IndiaBestCancerSurgeon #IndiaTopOncologist #MaharashtraBestCancerSurgeon #MaharashtraTopOncologist #AwardWinningCancerSurgeonPune #AwardWinningOncologistPune #30YearsExperienceCancerSurgeonPune #TataMemorialTrainedCancerSurgeonPune #FarisEdinburghTrainedSurgeonPune #EtOncoFrontiersAwardedSurgeonPune #NavbharatTimesBestRoboticOncosurgeon #MostQualifiedCancerSurgeonPune #HighlyQualifiedOncologistPune

GI & HPB CancerSurgery — Stomach,Colorectum,Pancreas & Liver

GI & HPB Oncology Surgery

GI & HPB Cancers — What We Treat

Gastric Cancer

Colorectal Cancer

Pancreatic Cancer

Liver Cancer

Gallbladder Cancer

Gastric Cancer Surgery — Gastrectomy & D2 Dissection

Robotic Gastrectomy — Full Information

Subtotal Gastrectomy

Total Gastrectomy

Proximal Gastrectomy

Robotic Gastrectomy with D2 LND

Colorectal Cancer Surgery — Colon & Rectum

Right Hemicolectomy

Left Hemicolectomy

Sigmoid Colectomy / High Anterior Resection

Rectal Cancer Surgery — TME, LAR & APR

Robotic Low Anterior Resection (LAR) — Full Information

Robotic Abdominoperineal Resection (APR) — Full Information

Low Anterior Resection (LAR)

Abdominoperineal Resection (APR)

Pancreatic Cancer — Whipple's Procedure & Beyond

Robotic Whipple's Surgery — Full Information

Staging Laparotomy / Laparoscopy

Pancreaticoduodenectomy — Resection

Pancreaticojejunostomy — Critical Anastomosis

Hepaticojejunostomy

Gastrojejunostomy / Duodenojejunostomy

Recovery & Adjuvant Treatment

Liver, Gallbladder & Bile Duct Cancer Surgery

Hepatocellular Carcinoma (HCC)

Colorectal Liver Metastases

Gallbladder Cancer

Cholangiocarcinoma

Peritoneal Metastases — HIPEC

Electrochemotherapy (ECT)

HIPEC — Full Information on Cytoreductive Surgery & Heated Chemotherapy

Frequently Asked Questions

Consult Dr. Gore for GI Cancer Surgery

Other Cancer Surgeries & Techniques

Thoracic Surgery

Gynaecological Cancers

HIPEC

ICG Fluorescence

Robotic Surgery

GI & HPB Cancer
Surgery — Stomach,
Colorectum,
Pancreas & Liver